| Primary |
| Glioma |
21.6% |
| Cytomegalovirus Infection |
12.3% |
| Antifungal Prophylaxis |
8.8% |
| Drug Use For Unknown Indication |
7.6% |
| Prophylaxis |
6.1% |
| Product Used For Unknown Indication |
5.8% |
| Prophylaxis Against Transplant Rejection |
4.4% |
| Idiopathic Thrombocytopenic Purpura |
4.1% |
| Crohn's Disease |
3.5% |
| Immunosuppression |
3.5% |
| Prophylaxis Against Graft Versus Host Disease |
3.2% |
| Hiv Infection |
2.6% |
| Lymphoproliferative Disorder |
2.6% |
| Diffuse Large B-cell Lymphoma |
2.3% |
| T-cell Lymphoma |
2.3% |
| Antiviral Prophylaxis |
2.0% |
| Colitis Ulcerative |
2.0% |
| Epstein-barr Virus Infection |
1.8% |
| Polyarteritis Nodosa |
1.8% |
| Cytomegalovirus Colitis |
1.5% |
|
| Cytomegalovirus Infection |
10.4% |
| Death |
9.1% |
| Aspergillosis |
7.8% |
| Pancytopenia |
7.8% |
| Tumour Lysis Syndrome |
7.8% |
| Renal Impairment |
6.5% |
| Diabetic Hyperosmolar Coma |
5.2% |
| Hydrocephalus |
5.2% |
| Thrombocytopenia |
5.2% |
| Bone Marrow Failure |
3.9% |
| Neutropenia |
3.9% |
| Renal Failure |
3.9% |
| Status Epilepticus |
3.9% |
| Ulcer |
3.9% |
| Blood Creatinine Increased |
2.6% |
| Epilepsy |
2.6% |
| Hemiparesis |
2.6% |
| Lung Transplant Rejection |
2.6% |
| Mycobacterium Avium Complex Immune Restoration Disease |
2.6% |
| Neutrophil Pelger-huet Anomaly Present |
2.6% |
|
| Secondary |
| Cytomegalovirus Infection |
13.0% |
| Product Used For Unknown Indication |
12.4% |
| Prophylaxis Against Transplant Rejection |
9.3% |
| Plasmablastic Lymphoma |
7.3% |
| Prophylaxis |
6.7% |
| Immunosuppression |
5.7% |
| Acquired Immunodeficiency Syndrome |
4.9% |
| Drug Use For Unknown Indication |
4.7% |
| Hiv Infection |
4.7% |
| Infection Prophylaxis |
4.4% |
| Crohn's Disease |
4.1% |
| Prophylaxis Against Graft Versus Host Disease |
3.6% |
| Lymphoproliferative Disorder |
3.4% |
| Pyrexia |
3.1% |
| Atrial Fibrillation |
2.3% |
| Stem Cell Transplant |
2.3% |
| Antifungal Prophylaxis |
2.1% |
| Idiopathic Thrombocytopenic Purpura |
2.1% |
| Pneumonia |
2.1% |
| Antiretroviral Therapy |
1.8% |
|
| Multi-organ Failure |
9.1% |
| Renal Impairment |
7.8% |
| Thrombotic Microangiopathy |
7.8% |
| Bone Marrow Failure |
6.5% |
| Pancytopenia |
6.5% |
| Transplant Rejection |
6.5% |
| Mycobacterium Avium Complex Immune Restoration Disease |
5.2% |
| Neutropenia |
5.2% |
| Petit Mal Epilepsy |
5.2% |
| Pneumonia Cytomegaloviral |
5.2% |
| Renal Failure |
5.2% |
| Respiratory Failure |
5.2% |
| Bone Marrow Toxicity |
3.9% |
| Nephropathy Toxic |
3.9% |
| Thrombocytopenia |
3.9% |
| Acute Respiratory Distress Syndrome |
2.6% |
| Aplasia |
2.6% |
| Blood Creatinine Increased |
2.6% |
| Cytomegalovirus Chorioretinitis |
2.6% |
| Cytomegalovirus Colitis |
2.6% |
|
| Concomitant |
| Immunosuppression |
16.2% |
| Product Used For Unknown Indication |
12.7% |
| Prophylaxis |
12.7% |
| Hiv Infection |
8.1% |
| Liver Transplant |
6.1% |
| Pneumocystis Jiroveci Pneumonia |
5.7% |
| Diabetes Mellitus |
4.8% |
| Stem Cell Transplant |
4.1% |
| Gastrointestinal Disorder |
3.9% |
| Vitamin Supplementation |
3.5% |
| Antiretroviral Therapy |
3.1% |
| B-cell Lymphoma |
3.1% |
| Upper Respiratory Tract Infection |
2.6% |
| Pain |
2.4% |
| Pulmonary Tuberculosis |
2.2% |
| Candidiasis |
2.0% |
| Premedication |
2.0% |
| Mineral Supplementation |
1.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.7% |
| Prophylaxis Against Transplant Rejection |
1.5% |
|
| Osteonecrosis |
11.1% |
| Respiratory Failure |
8.9% |
| Urinary Tract Infection |
8.9% |
| Aids Encephalopathy |
4.4% |
| Duodenitis |
4.4% |
| Dysphagia |
4.4% |
| Herpes Zoster |
4.4% |
| Liver Disorder |
4.4% |
| Overdose |
4.4% |
| Pharmaceutical Product Complaint |
4.4% |
| Pneumonia Cytomegaloviral |
4.4% |
| Pulmonary Oedema |
4.4% |
| Renal Tubular Necrosis |
4.4% |
| Status Epilepticus |
4.4% |
| Systemic Inflammatory Response Syndrome |
4.4% |
| Toxic Encephalopathy |
4.4% |
| Transplant Failure |
4.4% |
| Venoocclusive Liver Disease |
4.4% |
| Abdominal Pain |
2.2% |
| Bronchitis Bacterial |
2.2% |
|
